Literature DB >> 17244529

RACK1 competes with HSP90 for binding to HIF-1alpha and is required for O(2)-independent and HSP90 inhibitor-induced degradation of HIF-1alpha.

Ye V Liu1, Jin H Baek, Huafeng Zhang, Roberto Diez, Robert N Cole, Gregg L Semenza.   

Abstract

Hypoxia-inducible factor 1 (HIF-1) regulates transcription in response to changes in O(2) concentration. O(2)-dependent degradation of the HIF-1alpha subunit is mediated by prolyl hydroxylase (PHD), the von Hippel-Lindau (VHL)/Elongin-C/Elongin-B E3 ubiquitin ligase complex, and the proteasome. Inhibition of heat-shock protein 90 (HSP90) leads to O(2)/PHD/VHL-independent degradation of HIF-1alpha. We have identified the receptor of activated protein kinase C (RACK1) as a HIF-1alpha-interacting protein that promotes PHD/VHL-independent proteasomal degradation of HIF-1alpha. RACK1 competes with HSP90 for binding to the PAS-A domain of HIF-1alpha in vitro and in human cells. HIF-1alpha degradation induced by the HSP90 inhibitor 17-allylaminogeldanamycin is abolished by RACK1 loss of function. RACK1 binds to Elongin-C and promotes ubiquitination of HIF-1alpha. Elongin-C-binding sites in RACK1 and VHL show significant sequence similarity. Thus, RACK1 is an essential component of an O(2)/PHD/VHL-independent mechanism for regulating HIF-1alpha stability through competition with HSP90 and recruitment of the Elongin-C/B ubiquitin ligase complex.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17244529      PMCID: PMC2563152          DOI: 10.1016/j.molcel.2007.01.001

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  49 in total

1.  RACK1 and stratifin target DeltaNp63alpha for a proteasome degradation in head and neck squamous cell carcinoma cells upon DNA damage.

Authors:  Alexey Fomenkov; Rachel Zangen; Yi-Ping Huang; Motonobu Osada; Zhongmin Guo; Tanya Fomenkov; Barry Trink; David Sidransky; Edward A Ratovitski
Journal:  Cell Cycle       Date:  2004-10-06       Impact factor: 4.534

2.  OS-9 interacts with hypoxia-inducible factor 1alpha and prolyl hydroxylases to promote oxygen-dependent degradation of HIF-1alpha.

Authors:  Jin Hyen Baek; Patrick C Mahon; Jane Oh; Brian Kelly; Balaji Krishnamachary; Mia Pearson; Denise A Chan; Amato J Giaccia; Gregg L Semenza
Journal:  Mol Cell       Date:  2005-02-18       Impact factor: 17.970

Review 3.  Hypoxia preconditioning in the brain.

Authors:  Ruiqiong Ran; Huichun Xu; Aigang Lu; Myriam Bernaudin; Frank R Sharp
Journal:  Dev Neurosci       Date:  2005 Mar-Aug       Impact factor: 2.984

Review 4.  HSP90 and the chaperoning of cancer.

Authors:  Luke Whitesell; Susan L Lindquist
Journal:  Nat Rev Cancer       Date:  2005-10       Impact factor: 60.716

5.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.

Authors:  P H Maxwell; M S Wiesener; G W Chang; S C Clifford; E C Vaux; M E Cockman; C C Wykoff; C W Pugh; E R Maher; P J Ratcliffe
Journal:  Nature       Date:  1999-05-20       Impact factor: 49.962

6.  Concordant regulation of gene expression by hypoxia and 2-oxoglutarate-dependent dioxygenase inhibition: the role of HIF-1alpha, HIF-2alpha, and other pathways.

Authors:  Gareth P Elvidge; Louisa Glenny; Rebecca J Appelhoff; Peter J Ratcliffe; Jiannis Ragoussis; Jonathan M Gleadle
Journal:  J Biol Chem       Date:  2006-03-24       Impact factor: 5.157

Review 7.  Hsp90: a novel target for cancer therapy.

Authors:  David B Solit; Neal Rosen
Journal:  Curr Top Med Chem       Date:  2006       Impact factor: 3.295

8.  RACK1 mediates activation of JNK by protein kinase C [corrected].

Authors:  Pablo López-Bergami; Hasem Habelhah; Anindita Bhoumik; Weizhou Zhang; Lu-Hai Wang; Ze'ev Ronai
Journal:  Mol Cell       Date:  2005-08-05       Impact factor: 17.970

Review 9.  Inhibitors of the HSP90 molecular chaperone: current status.

Authors:  Swee Sharp; Paul Workman
Journal:  Adv Cancer Res       Date:  2006       Impact factor: 6.242

Review 10.  HIF-1 and tumour radiosensitivity.

Authors:  B J Moeller; M W Dewhirst
Journal:  Br J Cancer       Date:  2006-05-30       Impact factor: 7.640

View more
  209 in total

1.  COMMD1 disrupts HIF-1alpha/beta dimerization and inhibits human tumor cell invasion.

Authors:  Bart van de Sluis; Xicheng Mao; Yali Zhai; Arjan J Groot; Jeroen F Vermeulen; Elsken van der Wall; Paul J van Diest; Marten H Hofker; Cisca Wijmenga; Leo W Klomp; Kathleen R Cho; Eric R Fearon; Marc Vooijs; Ezra Burstein
Journal:  J Clin Invest       Date:  2010-05-10       Impact factor: 14.808

2.  GSK-3β regulates cell growth, migration, and angiogenesis via Fbw7 and USP28-dependent degradation of HIF-1α.

Authors:  Daniela Flügel; Agnes Görlach; Thomas Kietzmann
Journal:  Blood       Date:  2011-12-05       Impact factor: 22.113

Review 3.  Hold me tight: Role of the heat shock protein family of chaperones in cardiac disease.

Authors:  Monte S Willis; Cam Patterson
Journal:  Circulation       Date:  2010-10-26       Impact factor: 29.690

Review 4.  Complex role of the HIF system in cardiovascular biology.

Authors:  Gabor Czibik
Journal:  J Mol Med (Berl)       Date:  2010-06-24       Impact factor: 4.599

5.  Interaction with ErbB4 promotes hypoxia-inducible factor-1α signaling.

Authors:  Ilkka Paatero; Anne Jokilammi; Pekka T Heikkinen; Kristiina Iljin; Olli-Pekka Kallioniemi; Frank E Jones; Panu M Jaakkola; Klaus Elenius
Journal:  J Biol Chem       Date:  2012-02-03       Impact factor: 5.157

6.  Carbon monoxide promotes VEGF expression by increasing HIF-1alpha protein level via two distinct mechanisms, translational activation and stabilization of HIF-1alpha protein.

Authors:  Yoon Kyung Choi; Chun-Ki Kim; Hansoo Lee; Dooil Jeoung; Kwon-Soo Ha; Young-Guen Kwon; Kyu-Won Kim; Young-Myeong Kim
Journal:  J Biol Chem       Date:  2010-08-19       Impact factor: 5.157

7.  Targeted genes and interacting proteins of hypoxia inducible factor-1.

Authors:  Wei Liu; Shao-Ming Shen; Xu-Yun Zhao; Guo-Qiang Chen
Journal:  Int J Biochem Mol Biol       Date:  2012-05-31

8.  Using Molecular Biology to Develop Drugs for Renal Cell Carcinoma.

Authors:  C Lance Cowey; W Kimryn Rathmell
Journal:  Expert Opin Drug Discov       Date:  2008-03       Impact factor: 6.098

9.  Pharmacologic ascorbate (P-AscH-) suppresses hypoxia-inducible Factor-1α (HIF-1α) in pancreatic adenocarcinoma.

Authors:  Justin G Wilkes; Brianne R O'Leary; Juan Du; Adrienne R Klinger; Zita A Sibenaller; Claire M Doskey; Katherine N Gibson-Corley; Matthew S Alexander; Susan Tsai; Garry R Buettner; Joseph J Cullen
Journal:  Clin Exp Metastasis       Date:  2018-02-02       Impact factor: 5.150

10.  Mutant versions of von Hippel-Lindau (VHL) can protect HIF1α from SART1-mediated degradation in clear-cell renal cell carcinoma.

Authors:  Á Ordóñez-Navadijo; E Fuertes-Yebra; B Acosta-Iborra; E Balsa; A Elorza; J Aragonés; M O Landazuri
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.